Close

Drug Research

RedHill Biopharma secures expanded manufacturing for COVID-19 therapeutic candidate

RedHill Biopharma, a specialty biopharmaceutical company, has announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, currently in swiftly progressing global Phase II/III and US Phase II studies for severe COVID-19 pneumonia,...

BioIVT Launches HEPATOMUNE Kit to Facilitate Liver Toxicity and Inflammation Studies for Drug Discovery and Disease Research

BioIVT, a leading provider of research models and services for drug and diagnostic development, launched its HEPATOMUNE® kit, a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury. HEPATOMUNE cultures are composed of hepatocytes, stromal cells and...

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing. Under...

FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries

FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP  facility in Hillerød, Denmark, deploying...

Mapi Pharma Announces Commissioning of a Vaccine Production Facility to Support the Supply of COVID-19 Vaccines to Israel and EU Countries

Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, announced that it will dedicate capacity at its manufacturing facility to support the global effort to provide COVID-19 vaccination to Israel, the EU and globally. Mapi Pharma has state-of-the-art...

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming System

iBio, Inc., a biotech innovator and biologics contract manufacturing organization, announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi Biosolutions, Inc. (“Safi”) to evaluate iBio’s FastPharming® System for the expression of key proteins to...

Eisai enters joint research pact with four research organizations in Japan for development of therapeutics for novel COVID-19

Eisai Co Ltd announced that it has entered into a joint research agreement with four research organizations (KAN Research Institute, National Center for Global Health and Medicine, Nagasaki University, and Yokohama City University) in Japan concerning the “Development of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read